ERBB2 and breast carcinoma: No biological marker has been generally acknowledged as a cause of the poor prognosis of patients with advanced colorectal cancer (4), although Her2/Neu is regarded as a novel biological marker for breast cancer and is used for guiding the individualized treatment (5–7).